



Triple-Negative Breast Cancer: ESMO 2021 Industry Satellite Symposium See Beyond the Negatives Monday, 20th September 2021 | 18:45–20:15 CEST | Channel 6



Agenda



Welcome and introduction

Professor of Cancer Medicine and Lead, Centre for Experimental Peter Schmid (Chair) Cancer Medicine, Barts Cancer Institute, London, United Kingdom



Molecular heterogeneity in triple negative breast cancer (TNBC) – a shift from biomarkerspecific towards all-comers strategies

Medical Oncologist, University Hospitals Leuven – Gasthuisberg, Leuven, Belgium Kevin Punie



Current and future treatment opportunities in metastatic TNBC

Head of Breast Cancer Program, International Breast Cancer Center, Barcelona, Spain Javier Cortés



Antibody-drug conjugates (r)evolution in breast cancer

Associate Director of Clinical Research in Breast Oncology, Sara M. Tolaney Dana-Farber Cancer Institute, Boston, MA, USA

This symposium is sponsored and organised by Gilead and Gilead's medicines will be discussed at this meeting. August 2021 IHQ-TRO-0039

Live Q&A (All faculty)

